| Literature DB >> 28492036 |
Christina N Lawson1,2, Jasmine Hollinger1, Sumit Sethi3, Ife Rodney1, Rashmi Sarkar3, Ncoza Dlova4, Valerie D Callender1,2.
Abstract
Skin of color comprises a diverse and expanding population of individuals. In particular, women of color represent an increasing subset of patients who frequently seek dermatologic care. Acne, melasma, and alopecia are among the most common skin disorders seen in this patient population. Understanding the differences in the basic science of skin and hair is imperative in addressing their unique needs. Despite the paucity of conclusive data on racial and ethnic differences in skin of color, certain biologic differences do exist, which affect the disease presentations of several cutaneous disorders in pigmented skin. While the overall pathogenesis and treatments for acne in women of color are similar to Caucasian men and women, individuals with darker skin types present more frequently with dyschromias from acne, which can be difficult to manage. Melasma is an acquired pigmentary disorder seen commonly in women with darker skin types and is strongly associated with ultraviolet (UV) radiation, genetic factors, and hormonal influences. Lastly, certain hair care practices and hairstyles are unique among women of African descent, which may contribute to specific types of hair loss seen in this population, such as traction alopecia, trichorrhexis nodosa and central centrifugal cicatricial alopecia (CCCA).Entities:
Year: 2017 PMID: 28492036 PMCID: PMC5419061 DOI: 10.1016/j.ijwd.2017.02.006
Source DB: PubMed Journal: Int J Womens Dermatol ISSN: 2352-6475
Top Ten Dermatologic Conditions Among Caucasian Versus Skin of Color Patients in the United States.⁎
| Caucasians | African Americans | Asian or Pacific Islanders | Hispanics or Latinos |
|---|---|---|---|
| Actinic keratosis | Acne vulgaris | Acne vulgaris | Acne vulgaris |
| Acne vulgaris | Unspecified dermatitis or eczema | Unspecified dermatitis or eczema | Unspecified dermatitis or eczema |
| Benign neoplasm of the skin | Seborrheic dermatitis | Benign neoplasm of the skin | Psoriasis |
| Unspecified dermatitis or eczema | Atopic dermatitis | Psoriasis | Benign neoplasm of the skin |
| Non-melanoma skin cancer | Dyschromia | Seborrheic keratosis | Viral warts |
| Seborrheic keratosis | Psoriasis | Atopic dermatitis | Actinic keratosis |
| Viral warts | Alopecia | Viral warts | Seborrheic keratosis |
| Psoriasis | Keloid scar | Urticaria | Sebaceous cyst |
| Rosacea | Viral warts | Sebaceous cyst | Rosacea |
| Sebaceous cyst | Sebaceous cyst | Seborrheic dermatitis | Dyschromia |
Listed in order of decreasing frequency. Table adapted from Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012;11:466-73.
Comparison of the Structure and Function of Skin and Hair Between Caucasians and African Americans.⁎
| Caucasians | African Americans | Reference | |
|---|---|---|---|
| Stratum corneum thickness | Equal | Equal | |
| Stratum corneum layers | Less | More | |
| Stratum corneum lipids | Low | High | |
| Corneocyte detachment | High | Low | |
| Ceramide concentration | High | Low | |
| Melanin content | Low | High | |
| Melanosomes | Small, aggregated | Large, dispersed; higher number transferred to keratinocytes | |
| Dermis | Thin, less compact | Thick, more compact | |
| Papillary and reticular layers | More distinct | Less distinct | |
| Collagen fiber bundles | Larger | Smaller, closely stacked | |
| Fiber fragments | Sparse | Prominent, numerous | |
| Hair shaft structure | Straight or slightly curved | Tightly coiled, spiral | |
| Cross-section of hair | Slightly less round than Asian hair | Oval or elliptical shape | |
| Tensile strength of hair | Higher | Lower |
Table modified from Badreshia-Bansal S, Taylor S. The Structure and Function of Skin of Color. In: Kelly AP, Taylor SC, eds. Dermatology for skin of color. New York, NY: McGraw-Hill companies. 2009:71-77.
Fig. 1Acne in an African American female (Courtesy of Susan C. Taylor, MD, et al; from Treatments for Skin of Color, copyright Elsevier 2011).
Fig. 2Acne and Postinflammatory Hyperpigmentation (Courtesy of Valerie Callender, MD; Callender Dermatology & Cosmetic Center, Glenn Dale, MD).
Fig. 3Pomade acne. Note the closed comedones on the forehead and temples. (Courtesy of Valerie Callender, MD; from Treatments for Skin of Color by Susan C. Taylor, MD, et al, copyright Elsevier 2011).
Fig. 4Acne and PIH algorithm (Modified from Treatments for Skin of Color by Susan C. Taylor, MD, et al, copyright Elsevier 2011).
Review of Acne in Skin of Color.
| Authors | Study Design | Total # of Subjects (N) | Summary of Results | Level of Evidence | Strength of Recommendation |
|---|---|---|---|---|---|
| Single-center, randomized, double-blinded placebo-controlled study | 171 subjects (F=94; M = 77) | At 90 days of treatment, the efficacy rates of tretinoin 0.05% gel, adapalene 0.3% gel and adapalene 0.1% gel were 80%, 70%, and 59% respectively. | I | A | |
| Multicenter, randomized, double-blinded, vehicle-controlled study | 74 subjects (F=65; M=9) | Once-daily tazarotene 0.1% cream was significantly more effective than vehicle in lessening PIH overall (P = 0.010), and in reducing the intensity (P = 0.044) and area of hyperpigmented lesions (P = 0.026) within 18 weeks. | I | A | |
| Multicenter, randomized, double-blinded, placebo-controlled study | 238 subjects (F=166; M=72) | After 12 weeks, significant reductions in total, inflammatory and noninflammatory lesion counts were observed with adapalene 0.1%/BPO 2.5% gel than vehicle. | I | A | |
| Multicenter, randomized, double-blinded, vehicle-controlled study | 797 subjects (F=408; M=389) | Treatment success with clindamycin phosphate 1.2%/BPO 2.5% gel was comparable between FST I-III and FST IV-VI at week 12. | I | A | |
| Multicenter, randomized, double-blinded, placebo-controlled study | 33 subjects (F=26; M=7) | Clindamycin phosphate 1.2%/tretinoin 0.025% gel-treated patients had a greater decrease in inflammatory lesion counts from baseline than vehicle group at week 12 (P = 0.05). | I | B | |
| Single-center, open-label pilot study | 20 subjects (F=15; M=5) | At week 16, azelaic acid 15% gel applied twice daily resulted in 92% of subjects with at least a one-point improvement in IGA for acne and 100% of subjects had at least a 2-point improvement in IGA for PIH. | II-iii | B | |
| Multicenter, randomized, double-blinded, vehicle-controlled crossover study | 64 subjects (F=35; M=29) | Subjects with glucose-6-phosphate dehydrogenase deficiency (G6PD) treated with dapsone 5% gel had only a 0.32 g/dL decrease in hemoglobin levels from baseline to 2 weeks; however, no changes were noted in reticulocytes, haptoglobin, bilirubin or lactate dehydrogenase levels. | I | A | |
| Multicenter, randomized, double-blinded, placebo-controlled study | 1038 subjects (F=449; M=589) | An extended release formulation of minocycline hydrochloride was evaluated in subjects with moderate to severe acne in a phase 2 dose finding study and two phase 3 safety and efficacy trials. Study participants received minocycline 1 mg/kg daily or placebo over 12 weeks. | I | A | |
| Single-center, randomized controlled study | 386 subjects (F=215; M=171) | Subjects with moderate acne received either azithromycin 500 mg daily before meals for 4 consecutive days monthly for 3 months or doxycycline 100 mg daily after meals for 3 months and followed up after 3 months. An excellent response was noted in 3.1% and a good response was observed in 22.8% in the azithromycin group. In the doxycycline group, 11.4% had excellent and 55.4% had a good response. The authors concluded that doxycycline is the better treatment option for acne. | I | A | |
| Multicenter, randomized, controlled, noninferiority, investigator-blinded study | 266 subjects (F=39; M=227) | The efficacy and safety of oral isotretinoin versus doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO) was compared in subjects with severe nodular acne over 20 weeks. The authors found that D+A/BPO showed a favorable composite efficacy/safety profile compared with isotretinoin and concluded that this combination can be used as an alternative to isotretinoin in severe nodular acne. | I | A | |
| Case series | 10 subjects | 10 African American subjects with recalcitrant nodulocystic acne treated with isotretinoin developed an early onset flare of nodulocystic lesions at sites initially devoid of acne lesions at weeks 2-4. | II-iii | B | |
| Case series | 30 subjects (F=20; M=10) | Subjects with FST IV and V with atrophic ice pick acne scars were primed for 2 weeks (with hydroquinone 4% cream in the morning and tretinoin 0.025% cream at night) prior to receiving focal application of 100% trichloroacetic acid (TCA) to each scar at 2-week intervals for 4 sessions. | II-iii | C | |
| Case series | 5 subjects (F=3; M=2) | Subjects with FST IV and V treated with a novel superficial and deep AcuPulse MultiMode carbon dioxide (CO2) fractional laser had clinically significant improvement in acne and no reports of PIH were noted. | II-iii | C | |
| Case series | 20 subjects | Subjects with FST IV through VI treated with a nonablative 450-nm diode laser found it to be effective in improving the appearance of atrophic acne scars, however, PIH was common in 56% of subjects. | II-iii | C | |
| Multicenter, randomized, double-blinded, controlled study | 147 subjects (F = 90; M = 57) | Subjects with at least 4 moderate to severe rolling, atrophic scars randomly received polymethylmethacrylate (PMMA) suspended in bovine collagen (PMMA-collagen) or saline injections. Subjects underwent up to 2 injection sessions and were followed up for 6 months. Success was achieved by 64% of those treated with PMMA-collagen compared with 33% of control subjects (P = .0005). The treatment showed excellent safety with generally mild, reversible adverse events. No significant differences in efficacy or safety were noted between genders, for darker skin types, or in older age groups. | I | B |
* In accordance with the US Preventive Services Task Force levels of evidence for grading clinical trials (Sheth and Pandya, 2011b), (see Appendix A).
Abbreviations: F, female; M, male; BPO, benzoyl peroxide; PIH, postinflammatory hyperpigmentation; FST, Fitzpatrick skin type; IGA, investigator global assessment.
Fig. 5Melasma, malar variant (Courtesy of Jean Bolognia, MD; from Dermatology, copyright Elsevier, 3rd ed., 2012).
Fig. 6Melasma, centrofacial variant with sparing of the philtrum (Courtesy of Jean Bolognia, MD; from Dermatology, copyright Elsevier, 3rd ed., 2012).
Levels of evidence and strength of recommendations for various peeling agents in ethnic skin (Sarkar et al., 2012).
| Peeling agent | Level of evidence | Strength of recommendation |
|---|---|---|
| Glycolic acid peel | II-i | A |
| Lactic acid peel | II-iii | B |
| Salicylic acid peel | II-iii | B |
| Trichloroacetic acid peel | II-iii | B |
| Jessner’s solution | II-iii | B |
| Phytic acid peel | III | C |
| Pyruvic acid peel | III | C |
* In accordance with the US Preventive Services Task Force levels of evidence for grading clinical trials (Sheth and Pandya, 2011b), (see Appendix A).
Levels of evidence and strength of recommendations for lasers and light based devices for treating melasma in skin of color.
| Type of laser | Level of evidence | Strength of recommendation | Side effects and complications | |
|---|---|---|---|---|
| Q switched lasers | Q switched Ruby ( | II-iii | C | PIH and recurrence of melasma |
| Post operative discomfort | ||||
| Q switched Alexandrite ( | II-iii | C | PIH | |
| Q switched Nd:Yag-“laser toning/laser facial” ( | I | B | Erythema, burning, swelling, whitening of hair Spotty depigmentation | |
| Rebound hyperpigmentation | ||||
| Recurrence of melasma | ||||
| Light devices | IPL ( | II-iii | C | Erythema |
| Pain | ||||
| PIH | ||||
| Fractional Ablative lasers | Erbium:YAG ( | II-iii | C | PIH |
| CO2 ( | II-iii | C | PIH | |
| Rebound melasma | ||||
| Vascular lasers | PDL ( | II-iii | C | PIH |
| Fractional lasers | Non-ablative 1,550 nm fractional laser therapy | I | C | Erythema, burning sensation, edema, pain and PIH |
| 1,927-nm thulium fiber laser ( | II-iii | C | Moderate erythema and mild edema |
* In accordance with the US Preventive Services Task Force levels of evidence for grading clinical trials (Sheth and Pandya, 2011b), (see Appendix A).
Abbreviations: IPL, intense pulsed light; PDL, pulsed dye laser; PIH, postinflammatory hyperpigmentation.
Fig. 7(Left to right) Electric curling iron, hot comb and ceramic flat iron (Courtesy of Valerie Callender, MD; from Treatments for Skin of Color by Susan C. Taylor, MD, et al, copyright Elsevier 2011).
Fig. 8Chemical relaxer application to hair (Courtesy of Susan C. Taylor, MD, et al; from Treatments for Skin of Color, copyright Elsevier 2011).
Fig. 9Traction alopecia (Courtesy of Valerie Callender, MD; from Treatments for Skin of Color by Susan C. Taylor, MD, et al, copyright Elsevier 2011).
Fig. 10Trichorrhexis nodosa in the temporal scalp region (Courtesy of Valerie Callender, MD; from Treatments for Skin of Color by Susan C. Taylor, MD, et al, copyright Elsevier 2011).
Fig. 11Early stage CCCA (Courtesy of Susan C. Taylor, MD, et al; from Treatments for Skin of Color, copyright Elsevier 2011).
Fig. 12CCCA (Courtesy of Susan C. Taylor, MD, et al; from Treatments for Skin of Color, copyright Elsevier 2011).
Fig. 13CCCA in an African American woman (Courtesy of Jean Bolognia, MD; from Dermatology, copyright Elsevier, 3rd ed., 2012).
Fig. 14Late stage CCCA (Courtesy of Susan C. Taylor, MD, et al; from Treatments for Skin of Color, copyright Elsevier 2011).
Fig. 15FFA in an African American female. Note the symmetrical band-like loss of hair on the frontotemporal hairline and scalp. (Courtesy of Valerie Callender, MD; Callender Dermatology & Cosmetic Center, Glenn Dale, MD).
| Level of evidence | Quality of evidence |
|---|---|
| I | Evidence obtained from at least one properly designed, randomized controlled trial |
| II-i | Evidence obtained from well designed controlled trials without randomization |
| II-ii | Evidence obtained from well designed cohort or case control analytical studies, preferably from more than one center or research group |
| II-iii | Evidence obtained from multiple time series with or without the intervention; dramatic results in uncontrolled experiments could also be regarded as this type of evidence |
| III | Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees |
| IV | Evidence inadequate because of problems of methodology (eg, sample size or length of comprehensiveness of follow-up or conflicts in evidence) |